Compare Nutanix Inc (NTNX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs BIO-TECHNE Corp — how do they compare? Nutanix Inc trades at $64.31 (market cap $17.42B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Nutanix Inc is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Nutanix Inc pays none. Which is the better fit depends on your goals.
| NTNX | TECH | |
|---|---|---|
Market Cap | $17.42B | $11.24B |
Sector | Technology | Health |
52-Week High | $81.12 | $72.29 |
52-Week Low | $34.41 | $43.31 |
Enterprise Value | $16.94B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $62.67, up 4.24% today, with strong technical and fundamental momentum. The stock is near its 52-week high, supported by bullish moving averages and consistent earnings beats. Revenue growth is robust, with 2026 revenue projected at $2.7B and net profit margin improving to 10.03%. Recent news highlights institutional buying and positive analyst coverage, with 62.5% of analysts rating it a Buy.
Outlook remains positive due to earnings momentum and institutional interest, but risks include high valuation multiples and competitive pressures. The consensus price target is $57.80, slightly below current levels, suggesting near-term consolidation may occur. Investors should weigh growth prospects against elevated P/E and P/S ratios.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
